Headed by Gordon Mills and Rehan Akbanie, the MD Anderson GCC will use reverse phase protein arrays to investigate tumor tissue from a variety of NCI projects.
The firm is predicting a return to growth in its genotyping business later this year as it targets the single-cell analysis market with its eBioscience business.
A study involving more than 4,000 Huntington's disease cases led to variants on chromosomes 15 and 8 with ties to the age at which symptoms appear.
The firm posted revenues of $89 million driven by genetic analysis and product revenues, beating Wall Street estimates despite negative currency effects.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
In Science this week: caution urged in use of gene drives, and more.
NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.
PLOS Biology has asked researchers how they envision the future of genetics and genomics.
Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."